ReNAgade Therapeutics

ReNAgade Therapeutics

Develops RNA medicines for gene therapy

About ReNAgade Therapeutics

Simplify's Rating
Why ReNAgade Therapeutics is rated
B+
Rated B on Competitive Edge
Rated A on Growth Potential
Rated B on Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Series A

Total Funding

$300M

Headquarters

Cambridge, Massachusetts

Founded

2021

Overview

ReNAgade Therapeutics focuses on RNA medicine, aiming to address challenges in delivering RNA therapies to specific tissues and creating a comprehensive therapeutic platform. The company has developed a unique toolkit that enables precise correction of diseases on a large scale. Their business model leverages proprietary delivery technologies to access previously unreachable cells, enhancing gene expression through a collaboration with Orna Therapeutics. Unlike traditional gene therapy, which typically replaces defective genes, ReNAgade's approach seeks to permanently correct faulty genes, allowing for the insertion of exons or large genes. This positions ReNAgade as a leader in the Gene Therapy 2.0 space, targeting the genetic causes of diseases rather than just alleviating symptoms. The company serves clients in the medical and healthcare sectors, generating revenue through joint ventures, licensing its technologies, and potentially developing its own therapeutic products.

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in RNA therapies boosts ReNAgade's growth potential.
  • Advancements in LNP technology complement ReNAgade's RNA delivery systems.
  • FDA approvals of RNA therapies may streamline ReNAgade's regulatory pathway.

What critics are saying

  • Orna's acquisition may lead to strategic shifts affecting ReNAgade's projects.
  • Previous layoffs at Orna raise concerns about potential instability post-acquisition.
  • Integration of GanNA Bio's technology may delay new RNA medicine development.

What makes ReNAgade Therapeutics unique

  • ReNAgade Therapeutics offers a unique all-RNA system for gene correction and insertion.
  • The company collaborates with Orna Therapeutics to enhance RNA delivery technologies.
  • ReNAgade's proprietary toolkit allows precise disease correction on a large scale.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$300M

Above

Industry Average

Funded Over

1 Rounds

Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Above Average

Industry standards

$15M
$8.2M
Discord
$15M
Canva
$30M
Kalshi
$300M
ReNAgade Therapeutics

Company News

PR Newswire
May 23rd, 2024
Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies

/PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics...

BioPharma Dive
May 23rd, 2024
Orna, a circular RNA specialist, acquires a buzzy startup

After laying off staff late last year, Orna is now expanding through the purchase of ReNAgade Therapeutics, which was built around technology designed to more effectively deliver RNA-based medicines.

Business Wire
Apr 29th, 2024
Correcting And Replacing Renagade Therapeutics Continues Commitment To Ganna Bio And Glycan Biology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions. The updated release reads:. RENAGADE THERAPEUTICS CONTINUES COMMITMENT TO GANNA BIO AND GLYCAN BIOLOGY

Business Wire
Apr 27th, 2024
Renagade Therapeutics Poursuit Son Engagement Auprès De Ganna Bio Et De La Biologie Des Glycanes

CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--ReNAgade Therapeutics, une société qui exploite le potentiel illimité des médicaments à base d’ARN, a annoncé aujourd’hui son engagement continu à explorer l’opportunité thérapeutique que présente la glycobiologie en soutenant la recherche en cours chez GanNA Bio et en intégrant des personnes clés de GanNA Bio au sein de l’écosystème de ReNAgade. Les fondateurs de GanNA, Carolyn Bertozzi, Ph.D., et Richard D. Cummings, Ph.D., seront désormais conseillers de ReNAgade. « ReNAgade continuera à bénéficier énormément du travail prometteur de GanNA dans le développement d’une technologie d’administration extra-hépatique qui aide à élargir l’étendue et le potentiel de nos propres médicaments à base d’ARN », déclare Brian Goodman, cofondateur de ReNAgade. « L’administration est essentielle à la mission de ReNAgade, qui consiste à surmonter les limites actuelles des médicaments à base d’ARN. Nous pensons que la technologie développée au sein de GanNA contribuera à renforcer la position de leader de ReNAgade tandis que nous continuons à faire progresser notre plateforme thérapeutique unique et intégrée

Business Wire
Apr 27th, 2024
Renagadeセラピューティクス、Ganna Bioと糖鎖生物学に対するコミットメントを継続

米マサチューセッツ州ケンブリッジ--(BUSINESS WIRE)--(ビジネスワイヤ) --. RNA医薬品の無限の可能性にチャレンジする企業であるReNAgadeセラピューティクスは、GanNA Bioで現在進めている研究を支援し、同社のキーパーソンをReNAgadeのエコシステムに迎え入れることで、糖鎖生物学を活用した治療機会の探求に継続的に取り組むことを発表しました。GanNAの創設者であるキャロライン・ベルトッツィ博士とリチャード・D・カミングス博士は、今後ReNAgadeのアドバイザーを務めることになります。. 「GanNAが開発している肝外送達技術はReNAgade独自のRNA医薬品の幅と可能性を広げてくれます。当社はこうしたGanNAの将来有望な研究から、今後も多大な恩恵を受けることになるでしょう」と、ReNAgadeの共同創設者であるブライアン・グッドマンは述べています。「送達技術は、現在のRNA医薬品の限界を克服するというReNAgadeの使命の土台となるものです。GanNAが開発した技術により、ReNAgadeのリーダーとしての地位はさらに強固なものとなり、当社独自の統合治療プラットフォームはさらに発展すると確信しています。」

There are no jobs for ReNAgade Therapeutics right now.

Find jobs on Simplify and start your career today

💡
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →